Clinical Focus ›› 2023, Vol. 38 ›› Issue (5): 417-422.doi: 10.3969/j.issn.1004-583X.2023.05.005
Previous Articles Next Articles
Wang Yingnan1, Zhao Qi2, Bai Haiwei3, Wu Danna3, Wei Jinmei1, Li Shengjiang4, Li Ruiling5, Zhang Ruixing1()
Received:
2023-03-29
Online:
2023-05-20
Published:
2023-07-20
Contact:
Zhang Ruixing, Email:zrx@medmail.com.cn
CLC Number:
Wang Yingnan, Zhao Qi, Bai Haiwei, Wu Danna, Wei Jinmei, Li Shengjiang, Li Ruiling, Zhang Ruixing. Clinical characteristics and risk factors of gastric cancer-related stroke[J]. Clinical Focus, 2023, 38(5): 417-422.
Add to citation manager EndNote|Ris|BibTeX
URL: https://huicui.hebmu.edu.cn/EN/10.3969/j.issn.1004-583X.2023.05.005
组别 | 例数 | 性别 | 年龄 | 高血压史 | 糖尿病史 | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
男 | 女 | ≤60岁 | >60岁 | 有 | 无 | 有 | 无 | ||||||||||||
GCS组 | 42 | 34(81.0) | 8(19.0) | 9(21.4) | 33(78.6) | 21(50.0) | 21(50.0) | 12(28.6) | 30(71.4) | ||||||||||
对照组 | 84 | 68(81.0) | 16(19.0) | 24(28.6) | 60(71.4) | 23(27.4) | 61(72.6) | 6(7.1) | 78(92.9) | ||||||||||
χ2值 | 0.000 | 0.739 | 6.303 | 10.500 | |||||||||||||||
P值 | 1.000 | 0.390 | 0.012 | 0.001 | |||||||||||||||
组别 | 高脂血症史 | 冠心病史 | 吸烟史 | 饮酒史 | 既往脑梗死史 | ||||||||||||||
有 | 无 | 有 | 无 | 有 | 无 | 有 | 无 | 有 | 无 | ||||||||||
GCS组 | 9(21.4) | 33(78.6) | 8(19.0) | 34(81.0) | 18(42.9) | 24(57.1) | 13(31.0) | 29(69.0) | 23(54.8) | 19(45.2) | |||||||||
对照组 | 3(3.6) | 81(96.4) | 10(11.9) | 74(88.1) | 37(44.0) | 47(56.0) | 29(34.5) | 55(65.5) | 6(7.1) | 78(92.9) | |||||||||
χ2值 | 8.393 | 1.167 | 0.016 | 0.161 | 35.834 | ||||||||||||||
P值 | 0.004 | 0.280 | 0.899 | 0.688 | 0.000 |
Tab.1 Comparison of general demographic data between the two groups (n,%)
组别 | 例数 | 性别 | 年龄 | 高血压史 | 糖尿病史 | ||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
男 | 女 | ≤60岁 | >60岁 | 有 | 无 | 有 | 无 | ||||||||||||
GCS组 | 42 | 34(81.0) | 8(19.0) | 9(21.4) | 33(78.6) | 21(50.0) | 21(50.0) | 12(28.6) | 30(71.4) | ||||||||||
对照组 | 84 | 68(81.0) | 16(19.0) | 24(28.6) | 60(71.4) | 23(27.4) | 61(72.6) | 6(7.1) | 78(92.9) | ||||||||||
χ2值 | 0.000 | 0.739 | 6.303 | 10.500 | |||||||||||||||
P值 | 1.000 | 0.390 | 0.012 | 0.001 | |||||||||||||||
组别 | 高脂血症史 | 冠心病史 | 吸烟史 | 饮酒史 | 既往脑梗死史 | ||||||||||||||
有 | 无 | 有 | 无 | 有 | 无 | 有 | 无 | 有 | 无 | ||||||||||
GCS组 | 9(21.4) | 33(78.6) | 8(19.0) | 34(81.0) | 18(42.9) | 24(57.1) | 13(31.0) | 29(69.0) | 23(54.8) | 19(45.2) | |||||||||
对照组 | 3(3.6) | 81(96.4) | 10(11.9) | 74(88.1) | 37(44.0) | 47(56.0) | 29(34.5) | 55(65.5) | 6(7.1) | 78(92.9) | |||||||||
χ2值 | 8.393 | 1.167 | 0.016 | 0.161 | 35.834 | ||||||||||||||
P值 | 0.004 | 0.280 | 0.899 | 0.688 | 0.000 |
组别 | 例数 | WBC计数 (×109/L) | NEUT (×109/L) | RBC计数 (×1012/L) | HGB (g/L) | PLT (×109/L) | MPV (fL) | PT (s) | APTT (s) | FIB (g/L) | D-D (μg/ml) |
---|---|---|---|---|---|---|---|---|---|---|---|
GCS组 | 42 | 7.81±3.81 | 5.93±3.88 | 3.65±0.69 | 105.11±21.97 | 226.83±104.54 | 8.20±1.48 | 12.13±1.55 | 28.61±5.27 | 3.43±0.83 | 1.98±2.78 |
对照组 | 84 | 7.08±5.03 | 5.03±4.81 | 3.88±0.60 | 113.61±20.89 | 231.58±94.28 | 7.77±1.09 | 11.59±1.17 | 30.42±4.95 | 3.44±0.84 | 0.82±1.84 |
t值 | 0.829 | 1.051 | -1.956 | -2.116 | -0.257 | 1.809 | 2.201 | -1.894 | -0.013 | 2.463 | |
P值 | 0.409 | 0.295 | 0.053 | 0.036 | 0.798 | 0.073 | 0.030 | 0.061 | 0.990 | 0.017 |
Tab.2 Comparison of blood routine and coagulation function between the two groups ($\bar{x}\pm s$)
组别 | 例数 | WBC计数 (×109/L) | NEUT (×109/L) | RBC计数 (×1012/L) | HGB (g/L) | PLT (×109/L) | MPV (fL) | PT (s) | APTT (s) | FIB (g/L) | D-D (μg/ml) |
---|---|---|---|---|---|---|---|---|---|---|---|
GCS组 | 42 | 7.81±3.81 | 5.93±3.88 | 3.65±0.69 | 105.11±21.97 | 226.83±104.54 | 8.20±1.48 | 12.13±1.55 | 28.61±5.27 | 3.43±0.83 | 1.98±2.78 |
对照组 | 84 | 7.08±5.03 | 5.03±4.81 | 3.88±0.60 | 113.61±20.89 | 231.58±94.28 | 7.77±1.09 | 11.59±1.17 | 30.42±4.95 | 3.44±0.84 | 0.82±1.84 |
t值 | 0.829 | 1.051 | -1.956 | -2.116 | -0.257 | 1.809 | 2.201 | -1.894 | -0.013 | 2.463 | |
P值 | 0.409 | 0.295 | 0.053 | 0.036 | 0.798 | 0.073 | 0.030 | 0.061 | 0.990 | 0.017 |
肿瘤标记物 | 组别 | CEA(ng/ml) | AFP(ng/ml) | CA-199(U/ml) | CA-724(U/ml) |
---|---|---|---|---|---|
GCS组 | 42 | 39.31±68.25 | 7.93±20.95 | 185.03±317.85 | 81.43±229.18 |
对照组 | 84 | 84.28±240.41 | 11.33±54.93 | 83.82±197.54 | 12.75±36.72 |
t值 | -1.591 | -0.387 | 2.195 | 1.930 | |
P值 | 0.115 | 0.699 | 0.030 | 0.060 |
Tab. 3 Comparison of tumor markers between the two groups ($\bar{x}\pm s$)
肿瘤标记物 | 组别 | CEA(ng/ml) | AFP(ng/ml) | CA-199(U/ml) | CA-724(U/ml) |
---|---|---|---|---|---|
GCS组 | 42 | 39.31±68.25 | 7.93±20.95 | 185.03±317.85 | 81.43±229.18 |
对照组 | 84 | 84.28±240.41 | 11.33±54.93 | 83.82±197.54 | 12.75±36.72 |
t值 | -1.591 | -0.387 | 2.195 | 1.930 | |
P值 | 0.115 | 0.699 | 0.030 | 0.060 |
组别 | 例数 | 肿瘤部位[例(%)] | 分期[例(%)] | 放疗史[例(%)] | 手术史[例(%)] | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
胃食管结合部 | 非胃食管结合部 | Ⅰ~Ⅱ期 | Ⅲ~Ⅳ期 | 有 | 无 | 有 | 无 | ||||||||
GCS组 | 42 | 29(69.0) | 13(31.0) | 9(21.4) | 33(78.6) | 2(4.8) | 40(95.2) | 7(16.7) | 35(83.3) | ||||||
对照组 | 84 | 54(64.3) | 30(35.7) | 11(13.1) | 73(86.9) | 4(4.8) | 80(95.2) | 35(41.7) | 49(58.3) | ||||||
统计值 | χ2=0.282 | χ2=1.456 | χ2=0.000 | χ2=7.875 | |||||||||||
P值 | 0.595 | 0.228 | 1.000 | 0.005 | |||||||||||
组别 | 介入史[例(%)] | 化疗史[例(%)] | 化疗周期 | 靶向药物[例(%)] | |||||||||||
有 | 无 | 有 | 无 | 有 | 无 | ||||||||||
GCS组 | 3(7.1) | 39(92.9) | 24(57.1) | 18(42.9) | 5.92±5.84 | 2(8.3) | 22(91.7) | ||||||||
对照组 | 1(1.2) | 83(98.8) | 72(85.7) | 12(14.3) | 6.26±6.30 | 6(8.3) | 66(91.7) | ||||||||
统计值 | χ2=1.581 | χ2=12.600 | t=-1.772 | χ2=0.000 | |||||||||||
P值 | 0.209 | 0.000 | 0.079 | 1.000 |
Tab.4 Comparison of oncology data between the two groups
组别 | 例数 | 肿瘤部位[例(%)] | 分期[例(%)] | 放疗史[例(%)] | 手术史[例(%)] | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
胃食管结合部 | 非胃食管结合部 | Ⅰ~Ⅱ期 | Ⅲ~Ⅳ期 | 有 | 无 | 有 | 无 | ||||||||
GCS组 | 42 | 29(69.0) | 13(31.0) | 9(21.4) | 33(78.6) | 2(4.8) | 40(95.2) | 7(16.7) | 35(83.3) | ||||||
对照组 | 84 | 54(64.3) | 30(35.7) | 11(13.1) | 73(86.9) | 4(4.8) | 80(95.2) | 35(41.7) | 49(58.3) | ||||||
统计值 | χ2=0.282 | χ2=1.456 | χ2=0.000 | χ2=7.875 | |||||||||||
P值 | 0.595 | 0.228 | 1.000 | 0.005 | |||||||||||
组别 | 介入史[例(%)] | 化疗史[例(%)] | 化疗周期 | 靶向药物[例(%)] | |||||||||||
有 | 无 | 有 | 无 | 有 | 无 | ||||||||||
GCS组 | 3(7.1) | 39(92.9) | 24(57.1) | 18(42.9) | 5.92±5.84 | 2(8.3) | 22(91.7) | ||||||||
对照组 | 1(1.2) | 83(98.8) | 72(85.7) | 12(14.3) | 6.26±6.30 | 6(8.3) | 66(91.7) | ||||||||
统计值 | χ2=1.581 | χ2=12.600 | t=-1.772 | χ2=0.000 | |||||||||||
P值 | 0.209 | 0.000 | 0.079 | 1.000 |
危险因素 | β | SE | Wald χ2值 | P值 | OR值 | 95%置信区间 | |
---|---|---|---|---|---|---|---|
下限 | 上限 | ||||||
高血压病史 | 0.327 | 0.562 | 0.339 | 0.560 | 1.387 | 0.461 | 4.178 |
糖尿病病史 | 1.136 | 0.717 | 2.510 | 0.113 | 3.115 | 0.764 | 12.701 |
高脂血症史 | 0.972 | 0.845 | 1.322 | 0.250 | 2.643 | 0.504 | 13.851 |
既往脑梗死病史 | 2.962 | 0.610 | 23.560 | 0.000 | 19.341 | 5.848 | 63.964 |
HGB | -0.003 | 0.012 | 0.059 | 0.808 | 0.997 | 0.973 | 1.022 |
PT | 0.315 | 0.195 | 2.609 | 0.106 | 1.371 | 0.935 | 2.009 |
D-D | 0.150 | 0.115 | 1.699 | 0.192 | 1.162 | 0.927 | 1.455 |
CA-199 | 0.002 | 0.001 | 3.275 | 0.070 | 1.002 | 1.000 | 1.004 |
Tab. 5 Multivariate analysis of risk factors for patients with gastric cancer-related stroke
危险因素 | β | SE | Wald χ2值 | P值 | OR值 | 95%置信区间 | |
---|---|---|---|---|---|---|---|
下限 | 上限 | ||||||
高血压病史 | 0.327 | 0.562 | 0.339 | 0.560 | 1.387 | 0.461 | 4.178 |
糖尿病病史 | 1.136 | 0.717 | 2.510 | 0.113 | 3.115 | 0.764 | 12.701 |
高脂血症史 | 0.972 | 0.845 | 1.322 | 0.250 | 2.643 | 0.504 | 13.851 |
既往脑梗死病史 | 2.962 | 0.610 | 23.560 | 0.000 | 19.341 | 5.848 | 63.964 |
HGB | -0.003 | 0.012 | 0.059 | 0.808 | 0.997 | 0.973 | 1.022 |
PT | 0.315 | 0.195 | 2.609 | 0.106 | 1.371 | 0.935 | 2.009 |
D-D | 0.150 | 0.115 | 1.699 | 0.192 | 1.162 | 0.927 | 1.455 |
CA-199 | 0.002 | 0.001 | 3.275 | 0.070 | 1.002 | 1.000 | 1.004 |
[1] |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3) :209-249.
doi: 10.3322/caac.v71.3 URL |
[2] | Qiu H, Cao S, Xu R. Cancer incidence, mortality, and burden in China: A time-trend analysis and comparison with the United States and United Kingdom based on the global epidemiological data released in 2020[J]. Cancer Commun (Lond), 2021, 41(10):1037-1048. |
[3] | Motataianu A, Maier S, Gothard A, et al. Severe fatal systemic embolism due to non-bacterial thrombotic endocarditis as the initial manifestation of gastric adenocarcinoma: Case report[J]. Crit Care Med, 2018, 4(2):68-73. |
[4] | Tsuji H, Hara S, Urano J, et al. Good controlled chylothorax in gastric carcinoma[J]. Gan To Kagaku Ryoho, 2018, 45(10):1449-1451. |
[5] |
Selvik HA, Bjerkreim AT, Thomassen L, et al. When to screen ischaemic stroke patients for cancer[J]. Cerebrovasc Dis, 2018, 45(1-2):42-47.
doi: 10.1159/000484668 pmid: 29402826 |
[6] |
Cestari DM, Weine DM, Panageas KS, et al. Stroke in patients with cancer: Incidence and etiology[J]. Neurology, 2004, 62(11):2025-2030.
doi: 10.1212/01.wnl.0000129912.56486.2b pmid: 15184609 |
[7] |
Navi BB, Howard G, Howard VJ, et al. The risk of arterial thromboembolic events after cancer diagnosis[J]. Res Pract Thromb Haemost, 2019, 3(4):639-651.
doi: 10.1002/rth2.12223 pmid: 31624783 |
[8] | Aonuma AO, Nakamura M, Sakamaki K, et al. Incidence of cancer-associated thromboembolism in Japanese gastric and colorectal cancer patients receiving chemotherapy: A single-institutional retrospective cohort analysis (Sapporo CAT study)[J]. BMJ Open, 2019, 9(8) :e028563. |
[9] | Tetzlaff ED, Cheng JD, Ajani JA, et al. Thromboembolism in gastrointestinal cancers[J]. Gastrointest Cancer Res, 2008, 2(6): 267-272. |
[10] | Lin J, Wu S, Xu R, et al. Clinical characteristics and risk factors of lung cancer-associated acute ischemic stroke[J]. Biomed Res Int, 2019:6021037. |
[11] |
Saito E, Inoue M, Sawada N, et al. Risk of stroke in cancer survivors using a propensity score-matched cohort analysis. Sci Rep, 2021, 11(1) :5599.
doi: 10.1038/s41598-021-83368-w pmid: 33692383 |
[12] |
Majmudar K, Golemi I, Tafur AJ, et al. Outcomes after venous thromboembolism in patients with gastric cancer: Analysis of the RIETE Registry[J]. Vasc Med, 2020, 25(3):210-217.
doi: 10.1177/1358863X19893432 pmid: 32000631 |
[13] | 白海威, 祝琳, 刘畅, 等. 非神经系统恶性肿瘤患者围术期缺血性脑卒中的研究进展[J]. 实用心脑肺血管病杂志, 2020, 28(7):6-11. |
[14] |
Wei YC, Chen KF, Wu CL, et al. Stroke rate increases around the time of cancer diagnosis[J]. Front Neurol, 2019, 10:579.
doi: 10.3389/fneur.2019.00579 URL |
[15] | 陶正平, 宋文灿, 程元骏. 非脑部恶性肿瘤患者发生脑梗死危险因素分析[J]. 创伤与急危重病医学, 2022, 10(3):228-231. |
[16] | 王权, 何慧薇. 老年贫血与其他疾病相关性回顾分析[J]. 实用老年医学, 2020, 34(4):4. |
[17] |
Long H, Qin K, Chen J, et al. Biomarkers of gastric cancer-related ischemic stroke and its underlying pathogenesis[J]. Medicine (Baltimore), 2018, 97(17):e0493.
doi: 10.1097/MD.0000000000010493 URL |
[18] |
Di Castelnuovo A, Agnoli C, de Curtis A, et al. Elevated levels of D-dimers increase the risk of ischaemic and haemorrhagic stroke.Findings from the EPICOR study[J]. Thromb Haemost, 2014, 112(5):941-946.
doi: 10.1160/th14-04-0297 URL |
[19] | Shen Y, Li Y, Chen C, et al. D-dimer and diffusion-weighted imaging pattern as two diagnostic indicators for cancer-related stroke: A case-control study based on the STROBE guidelines[J]. Medicine (Baltimore), 2020, 99(4):e18779. |
[20] |
Ikushima S, Ono R, Fukuda K, et al. Trousseau's syndrome:Cancer-associated thrombosis[J]. Jpn J Clin Oncol, 2016, 46(3):204-208.
doi: 10.1093/jjco/hyv165 URL |
[21] | Bao L, Zhang S, Gong X, et al. Trousseau syndrome related cerebral infarction: Clinical manifestations, laboratory findings and radiological features[J]. J Stroke Cerebrovasc Dis. 2020, 29(9):104891. |
[22] | 国丽茹, 李彦青, 王澜涛, 等. 以多发急性脑梗死为首发表现的Trousseau综合征12例临床分析[J]. 中华全科医师杂志, 2019, 18(5):479-482. |
[23] |
Davies A, Van Leer L, Chan J, et al. Stroke in patients with cancer in the era of hyper-acute stroke intervention[J]. Intern Med J, 2022, 52(9):1513-1518.
doi: 10.1111/imj.v52.9 URL |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||